DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Cervical A | Acinar Cell Carcinoma | Appendix Mucinous Adenocarcinoma | Bronchioloalveolar Carcinoma | Adrenal Cortex Carcinoma | Bladder Adenocarcinoma | Adrenal Gland Pheochromocytoma | Anal Canal Undifferentiated Carcinoma | Anal Canal Neuroendocrine Carcinoma
Age: Between 18 - 100 Years
Gender: Male or Female
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 "National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH)" protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, "NCI-MATCH"
- Patients that are determined to have a rare cancer with unknown primary site are eligible provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required